Market Eli Lilly upgraded to buy at Mizuho on positive donanemab data January 19, 2021 Facebook Twitter Pinterest WhatsApp Linkedin ReddIt Email Eli Lilly upgraded to buy at Mizuho on positive donanemab data READ SOURCE READ Route Mobile: What should investors do after the 105% stellar listing gain?